MG
DMK

Michael Gelband’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Michael Gelband’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-918
Closed -$136K – 1389
2019
Q1 		$136K Buy
918
+747
+437% +$144K 0.01% 598
2018
Q4 		$27K Buy
+171
New +$32.8K ﹤0.01% 334

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Michael Gelband's DMK Position: Q2 2019 in Review

Michael Gelband sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2019, closing a stake of 918 shares — an estimated $136K sold.

Michael Gelband first reported a position in DMK in Q4 2018 and held it in 2 quarters. The position peaked at $136K in Q1 2019. 51 funds tracked by Wall St. Rank hold DMK as of Q2 2019.

  • Michael Gelband reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2019 after selling out during the quarter.
  • Michael Gelband sold 918 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2019, an estimated $136K.
  • Michael Gelband first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2018 and held it in 2 quarters.
  • Michael Gelband's DMK Pharmaceuticals Corporation Common Stock position peaked at $136K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2019.

Based on ExodusPoint Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.